FDA Advisory Committee does not recommend that sotagliflozin receive approval for glucose lowering in adults with type 1 diabetes (T1D) and Chronic Kidney Disease (CKD)
There is a deep unmet need for therapies in addition to insulin for glucose control in people with T1D. This…
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential…
EASD highlights Breakthrough T1D research
The research presented at EASD covered Breakthrough T1D’s entire research portfolio, encompassing disease-modifying therapies, cell therapies, and complications.
Veronica Beard Gives Back to Breakthrough T1D
New York-based fashion brand Veronica Beard is giving back to the type 1 diabetes community through customer donations, in-store events,…
Navigating the school year with type 1 diabetes: A call to support and action
A T1D dad and physician's POV about the start of a new school year.
Strength, struggle, and resilience: my mom’s journey with T1D
Though I do not live with type 1 diabetes (T1D) myself, I have witnessed firsthand the strength of those who…
At ADA 2024, Breakthrough T1D-funded research takes center stage
Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary…
ADA Takeaways: Day 2
At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for…
Breakthrough T1D Spearheads the Formation of Monitoring Guidelines
We spearheaded an effort to develop the first internationally agreed-upon guidance for anyone who tests positive for T1D autoantibodies.
Advocating for progress and access
With the support of our grassroots advocates, our work helps advance treatments, influence policy, and improve access to care for…